Nephroblastoma, a rare kidney cancer also known as Wilms' tumor, primarily affects young individuals. Most cases occur in children aged 3 to 4, with fewer occurrences after age 5. While it can sometimes affect both kidneys simultaneously, nephroblastoma usually targets only one kidney. The development of cancer in nephroblastoma is triggered by DNA errors within kidney cells, leading to uncontrolled growth and division of cells, ultimately resulting in tumor formation.
The market for nephroblastoma treatment is projected to grow due to increasing approvals by regulatory bodies for key players in the industry. These players are actively seeking approvals for drugs used in treating nephroblastoma, leading to market expansion. Additionally, the market is anticipated to experience growth through research and development efforts undertaken by key players in the field, specifically aimed at enhancing nephroblastoma treatment options. These activities are expected to propel market growth in the foreseeable future.
The projected worth of the global Nephroblastoma Treatment Market in 2022 is approximately US$ 1,653.0 million, with a predicted compound annual growth rate (CAGR) of 4.6% from 2022 to 2030.
Major Players in the Nephroblastoma Treatment Industry:
Merck & Co., Inc.
Merck & Co., Inc., was established in 1891 and is headquartered in Rahway, New Jersey, United States. It operates in over 191 countries and is engaged in developing medicines, vaccines, biologic therapies, and animal health products.
Pfizer Inc.
Pfizer Inc. was established in 1849 and is headquartered in New York, United States. It operates in 181 countries and is engaged in various industries, including biotechnology, healthcare, medical, and pharmaceuticals.